<b><i>Conclusions:</i></b> FCL insulin delivery with CamAPS HX improved glucose outcomes compared with insulin pump therapy with CGM in adolescents with T1D and HbA1c above target. This evidence concerns the gene INS and type 1 diabetes mellitus.